重组病毒检测肺癌患者活性循环肿瘤细胞的临床意义
该研究纳入63例肺癌患者、21例良性肺疾病患者和18名健康对照,采用含重组病毒的CTC体外检测试剂盒检测外周血活性CTC。结果显示该法敏感度89%(56/63)、特异度90%(35/39),不同病理类型及分期患者CTC阳性率差异无统计学意义。
要点
- 该CTC检测系统敏感度89%、特异度90%,可作为肺癌辅助诊断的简便无创方法。
- 腺癌、鳞癌、小细胞癌CTC阳性率分别为84%、92%、100%,组间差异无统计学意义。
- 不同临床分期患者CTC阳性率差异无统计学意义(χ²=3.419,P>0.05)。
核心结论
- 含重组病毒的CTC体外检测系统是辅助诊断肺癌的简便、无创方法,敏感度和特异度较高。
研究设计与样本
- 回顾性纳入2017年6月至2018年8月北京安贞医院确诊肺癌患者63例(腺癌38例、鳞癌13例、小细胞癌12例)。
- 良性肺疾病组21例,健康对照组18名,比较各组活性CTC阳性率。
主要发现
- 肺癌组、良性肺疾病组、健康对照组活性CTC阳性例数分别为56、4、0。
- 敏感度为89%(56/63),特异度为90%(35/39)。
- 腺癌、鳞癌、小细胞癌CTC阳性率分别为84%(32/38)、92%(12/13)、100%(12/12)。
- 腺癌和鳞癌患者Ⅰ期2例均阳性,Ⅱ期8例中6例阳性,Ⅲ期8例中7例阳性,Ⅳ期33例中29例阳性。
关键数值与推荐
- 不同病理分型间CTC阳性率差异无统计学意义(χ²=1.881,P>0.05)。
- 不同临床分期间CTC阳性率差异无统计学意义(χ²=3.419,P>0.05)。
临床怎么用
- 该检测简便无创,可用于肺癌的辅助诊断;不同病理类型和分期间阳性率无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical significance of recombinant virus-specific detection for detecting viable circulating tumor cell (CTC) in lung cancer patients. Methods: From June 2017 to August 2018, 63 lung cancer patients diagnosed by imaging and pathology at the Department of Respiratory and Critical Care Medicine, Beijing Anzhen Hospital were recruited for this study, including 38 cases of adenocarcinoma, 13 squamous cell carcinoma, and 12 small cell carcinoma. The patients consisted of 36 males and 27 females, with an average age of (65±11) years. In addition,21 patients with benign lung diseases were recruited for benign lung disease group, including 11 males and 10 females with an average age of (57±13) years. Another 18 healthy subjects were recruited for the healthy control group, including 10 males and 8 females, with an average age of (32±10) years. The peripheral blood viable CTCs were detected by a CTC in vitro detection kit containing recombinant virus. Fisher's exact test was used to compare the differences between the groups of viable CTC positive rates. Results: Cases with positive viable CTC in the lung cancer group, the benign lung disease group and the healthy control group were 56,4 and 0, respectively. The sensitivity and specificity of this CTC detection system were 89% (56/63) and 90% (35/39) , respectively. The positive rate of CTC detection for lung cancer patients with adenocarcinoma, aquamous cell carcinoma, and small cell carcinoma, were 84%(32/38), 92% (12/13) and 100% (12/12), respectively. The positive cases from adenocarcinoma and squamous cell carcinoma patients with different stages were 2 (n=2) in stageⅠ,6 (n=8) in stage Ⅱ,7(n=8) in stage Ⅲ and 29(n=33) in stage Ⅳ. There were no significant differences in the positive rates of CTC among different histological types or different stages (χ(2)=1.881, 3.419; P>0.05) . Conclusion: This CTC detection system was found to be a simple and non-invasive method for auxiliary diagnosis of lung cancer, with high sensitivity and specificity. 目的: 初步探讨重组病毒特异性检测肺癌患者外周血活性循环肿瘤细胞(CTC)的临床意义。 方法: 纳入首都医科大学附属北京安贞医院呼吸与危重症医学科2017年6月至2018年8月住院且经影像及病理学检查确诊的肺癌患者63例(肺癌组),其中腺癌38例,鳞癌13例,小细胞癌12例;男36例,女27例,平均年龄(65±11)岁;纳入同期本科室住院的21例良性肺疾病患者(良性肺疾病组),男11例,女10例,平均年龄(57±13)岁;本院健康体检者18名(健康对照组),男10名,女8名,平均年龄(32±10)岁。应用含重组病毒的CTC体外检测试剂盒检测肺癌组外周血中活性CTC数,并与另外2组进行比较。采用Fisher精确检验比较CTC阳性检出率的组间差异。 结果: 肺癌组56例活性CTC阳性;良性肺疾病组4例活性CTC阳性,健康组未检出;该检测方法的敏感度为89%(56/63),特异度为90%(35/39)。肺癌组腺癌患者中CTC阳性率为84%(32/38),鳞癌为92%(12/13),小细胞癌12例均阳性;肺腺癌和鳞癌患者活性CTC阳性分布:Ⅰ期2例均阳性,Ⅱ期8例中6例阳性,Ⅲ期8例中7例阳性,Ⅳ期33例中29例阳性。肺癌组不同病理分型、不同临床分期患者CTC阳性率比较差异无统计学意义(χ(2)=1.881和3.419,均P>0.05)。 结论: 重组病毒特异性检测肺癌患者外周血中活性CTC的方法简便、无创,且敏感度和特异度较高。.
引用
- Xiao Y, Liu S, Wang ZZ, et al. [Clinical significance of recombinant virus-specific detection for viable circulating tumor cells in lung cancer patients]. Zhonghua Jie He He Hu Xi Za Zhi. 2019. PMID: 30704181. doi:10.3760/cma.j.issn.1001-0939.2019.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。